Published in Breast Cancer Res Treat on May 01, 2002
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A (2007) 2.11
Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One (2014) 1.49
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Identification of arsenic-binding proteins in human breast cancer cells. Cancer Lett (2007) 1.01
Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci (2012) 0.91
Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol (2003) 0.91
Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PLoS One (2012) 0.89
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur J Nucl Med Mol Imaging (2008) 0.80
A new strategy to target regulatory T cells in solid tumors. Oncoimmunology (2013) 0.77
Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro. Contemp Oncol (Pozn) (2015) 0.77
Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Oncol (2014) 0.76
Arsenic Trioxide Negatively Affects Echinococcus granulosus. Antimicrob Agents Chemother (2015) 0.75
Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment: Assessment of Apoptotic Mechanisms and Oxidative Damage. J Cancer Sci Ther (2015) 0.75
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev (2008) 2.92
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
Functional role and prognostic significance of CD157 in ovarian carcinoma. J Natl Cancer Inst (2010) 2.08
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
CD39 and control of cellular immune responses. Purinergic Signal (2007) 1.68
CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood (2004) 1.63
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci (2006) 1.55
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood (2011) 1.53
GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes (2004) 1.41
Delayed postpartum hemorrhage: the implications of making a diagnostic mistake. Arch Gynecol Obstet (2012) 1.38
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood (2007) 1.35
Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res (2010) 1.35
Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. PLoS One (2011) 1.34
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res (2009) 1.34
CD38 and chronic lymphocytic leukemia: a decade later. Blood (2011) 1.33
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci (2004) 1.29
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
CD molecules 2006--human cell differentiation molecules. J Immunol Methods (2006) 1.23
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood (2005) 1.20
Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell (2007) 1.19
Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol (2007) 1.18
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res (2011) 1.13
Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes (2011) 1.13
CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol (2004) 1.11
CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood (2007) 1.11
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum (2002) 1.10
Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol (2008) 1.10
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol Med (2007) 1.08
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology (2013) 1.07
Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. Exp Cell Res (2010) 1.06
Differential expression of microRNAs between eutopic and ectopic endometrium in ovarian endometriosis. J Biomed Biotechnol (2010) 1.06
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. J Immunol Methods (2008) 1.06
CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor. J Biol Chem (2003) 1.05
Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr Rev (2011) 1.04
CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. J Biol Chem (2001) 1.03
IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol (2008) 1.03
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res (2011) 1.02
Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol (2007) 1.01
CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom (2013) 1.01
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol (2012) 1.01
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood (2002) 1.00
The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica (2013) 1.00
Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest (2013) 0.99
acDCs enhance human antigen-specific T-cell responses. Blood (2011) 0.98
Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis (2007) 0.98
Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms. J Immunol Methods (2010) 0.97
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica (2009) 0.97
Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med (2011) 0.97
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol (2011) 0.97
T cells in the pathogenesis of type 1 diabetes. Curr Diab Rep (2008) 0.96
Interobserver variability of colposcopic interpretations and consistency with final histologic results. J Low Genit Tract Dis (2004) 0.96
CD157, the Janus of CD38 but with a unique personality. Cell Biochem Funct (2002) 0.96
CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med (2008) 0.96
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med (2013) 0.95
Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood (2008) 0.95
Chemotaxis of human tonsil B lymphocytes to CC chemokine receptor (CCR) 1, CCR2 and CCR4 ligands is restricted to non-germinal center cells. Int Immunol (2002) 0.95
CD157 is an important mediator of neutrophil adhesion and migration. Blood (2004) 0.94
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood (2008) 0.94
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol (2012) 0.94
The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med (2007) 0.94
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica (2011) 0.93
CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med (2009) 0.93
All-trans retinoic acid upregulates reduced CD38 transcription in lymphoblastoid cell lines from Autism spectrum disorder. Mol Med (2011) 0.93
Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology (2007) 0.92
A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol (2011) 0.92
Measurement of CD8 T cell responses in human type 1 diabetes. Ann N Y Acad Sci (2008) 0.91
Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol (2003) 0.91